Center for Cognitive and Memory Disorders, Center for Neuromodulation

ScharreDouglasProfessor of Clinical Neurology and Psychiatry

395 W. 12th Ave.
Phone: 614-293-4969

Research Interests: Cognitive assessment, dementia, Alzheimer’s disease, mild cognitive impairment, dementia with Lewy bodies, frontotemporal dementia, behavioral disturbances in dementia.

Research Lab Goals: Dr. Scharre conducts clinical research in dementia and mild cognitive impairment that has been funded by NIH, foundations and industry. He has many active grants including clinical drug trials using cognitive enhancers and behavioral therapies; functional neuroimaging studies using PET, SPECT and MRI; and screening for mild cognitive impairment and early dementia diagnosis. He has published journal papers, book chapters and abstracts in the area of cognitive neurology including dementia, Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, Huntington's disease, chorea-acanthocytosis, frontal lobe disorders, inherited neurologic disorders, visual agnosia and optic aphasia. He has published on the neuropsychiatric aspects of neoplastic, demyelinating, infectious and inflammatory diseases of the brain; on biomarkers in Alzheimer's disease including beta-amyloid protein and tau protein; on functional neuroimaging with SPECT scanning; and on treatment of behavioral disturbances in dementia. He lectures frequently on topics of dementia, Alzheimer's disease, behavioral management of dementi, and other aspects of cognitive neurology.

Current Research:

  1. Merck. Scharre (Site PI). 03/04/2015 – 12/31/2018. A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 with a Long Term Double-Blind Extension in Subjects with Mild to Moderate Alzheimer's Disease
  2. FORUM Pharmaceuticals. Scharre (Site PI). 04/18/2014 – 12/30/2017. A Randomized, Double Blind, Placebo-Controlled Parallel-Group, 26-week, phase 3 Study of Two Doses of EVP-6124 in Subjects with Mild to Moderate Alzheimer's Disease Currently or Previously Receiving Acetycholinesterase Inhibitor Medication
  3. Lunbeck. Scharre (Site PI). 03/01/2014 – 12/30/2017. An Open Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lu AE58054 as Adjunctive Treatment to Donepezil in Patients with Mild-Moderate Alzheimer's Disease
  4. Merck. Scharre (Site PI). 05/05/2014 – 12/30/2017. A Seamless, Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy to Donepezil for Symptomatic Treatment in Subjects with Alzheimer's Disease
  5. Merck. Scharre (Site PI). 03/01/2014 – 12/30/2017. A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (prodromal AD)
  6. Brain Test, Inc.. Scharre (PI). 07/01/2014 - 08/01/2015. Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE).
  7. Lunbeck. Scharre (Site PI). 03/01/2014 – 12/30/2017. Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study of LuAE58054 in Patients with Mild-Moderate Alzheimer's Disease Treated with Donepezil
  8. Lilly. Scharre (Site PI). 11/15/2013 – 12/30/2017. Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo
  9. Ali Rezai, MD. Scharre (Co-PI). 06/29/2011 – 12/31/2016. Deep Brain stimulation (DBS) for Treatment of the Cognitive, Behavioral, and Functional Disability of Alzheimer’s Disease.
  10. Phylogeny, Inc. Scharre (PI). 01/01/2012 - 01/01/2016. Cerebral Fluid (CSF) and Blood Repository (Buckeye Biospecimen Repository): Evaluating Biomarkers for Degenerative Brain Conditions
  11. Mangurian Foundation. Scharre (PI). 01/14/2011 – 12/31/2018. Diagnosing Dementia with Lewy Bodies and Parkinson’s Disease Dementia
  12. NIA/pharmaceutical corporations. Scharre (Site PI). 10/01/2010 - 08/31/2015. Alzheimer’s Disease Neuroimaging Initiative 2 (ADNI2).

Research Techniques: neuroimaging, PET, MRI, lumbar puncture with cerebrospinal analysis, cognitive assessments

PubMed articles

Background: Dr. Scharre received his medical degree from Georgetown University and completed his neurology residency at Letterman Army medical Center in San Francisco. After completing a Neurobehavior fellowship at UCLA, he joined The Ohio State University Wexner Medical Center faculty in the Department of Neurology in 1993. Dr. Scharre is a board-certified neurologist with special interests in dementia-related behaviors and degenerative dementias.

BS, Physics & Biology, University of California, Los Angles (UCLA), CA, 1974-1978
MS, Physiology & Biophysics, Georgetown University, Washington, DC, 1978-1979
MD, Medicine, Georgetown University, Washington, DC, 1979-1983
Internship, Internal Medicine Wm Beaumont Army Medical Center, El Paso, TX, 1983-1984
Residency, Neurology, Letterman Army Medical Center, SF, CA, 1984-1987
Fellowship, Neurobehavior, University of California, Los Angeles (UCLA), CA, 1991-1993

My Clinical Bio

Share this Page